November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Atezolizumab Receives Priority Review Designation From FDA for Frontline Treatment of TNBC
November 13th 2018A supplemental biologics license application for the frontline combination of atezolizumab plus nab-paclitaxel has been granted a priority review by the FDA for the treatment of patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, based on data from the phase III IMpassion130 trial.
Read More
Early-Stage, Metastatic Settings Equivalent for Evaluating Biosimilarity
November 7th 2018According to findings of a systematic literature review presented at the 2018 ESMO Congress, the neoadjuvant and metastatic breast cancer settings are appropriate areas to evaluate the equivalence of biosimilars and originator products.
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
Entrectinib Induces Responses Across Multiple Tumor Types
October 22nd 2018Among patients with advanced solid tumors associated with <em>NTRK</em> gene fusions, more than half had responses to the small-molecule inhibitor entrectinib, according to an integrated analysis of 3 clinical trials presented at the 2018 ESMO Annual Congress.
Read More
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More
SOLAR-1 Trial Results Demonstrate a Benefit for Genomic Testing in Breast Cancer
October 21st 2018Lead investigator Fabrice André, MD, PhD, said findings from the SOLAR-1 trial are the first to show benefit in a genomic subgroup of patients with breast cancer and could open the door for genomic testing in breast cancer.
Read More
PALOMA-3 Analysis Finds Improved OS in Pretreated HR+/HER2- Breast Cancer
October 21st 2018In results from an analysis of the phase III PALOMA-3 trial, patients with hormone receptor-positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy achieved a clinically meaningful benefit in overall survival from the combination of palbociclib plus fulvestrant.
Read More
Frontline Atezolizumab and Nab-Paclitaxel Demonstrate PFS Benefit in PD-L1+ mTNBC
October 20th 2018The combination of atezolizumab and nab-paclitaxel demonstrated a 2.5-month benefit in progression-free survival over nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer, according to findings of the phase III IMpassion130 trial presented at the 2018 ESMO Congress.
Read More
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?
October 19th 2018Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Read More
Induction Chemo Turns Cold Tumors Hot in Metastatic TNBC
October 17th 2018In results presented at the European Society for Medical Oncology’s 2018 Molecular Analysis for Personalised Therapy Congress, Marlene Kok, MD, PhD, said results from the phase II TONIC study showed that induction therapy with doxorubicin turned “cold” tumor cells “hot,” resulting in an objective response rate of 20% following treatment with nivolumab.
Read More
Burstein Examines Predictive Value in Genomic Tests for Breast Cancer
October 17th 2018Genomic assays and signatures are increasingly being used as a prognostic indicator for guiding treatment decisions, according to Harold J. Burstein, MD, PhD. During a presentation at the 2018 Lynn Sage Breast Cancer Symposium in Chicago, he explained that many of these tests can also be used as predictive indicators.
Read More
Talazoparib Receives FDA Approval in BRCA-Mutated, HER2-Negative Breast Cancer
October 16th 2018Talazoparib has been approved by the FDA for treatment of patients with deleterious or suspected deleterious germline <em>BRCA</em>-mutated, HER2-negative locally advanced or metastatic breast cancer, according to Pfizer, the manufacturer of the PARP inhibitor.
Read More
Benefit From Adjuvant Chemotherapy Seen in Younger Women With Breast Cancer
October 16th 2018Although, it is challenging to determine the optimal adjuvant therapy for younger patients with breast cancer, Mark Robson, MD, encouraged that the addition of adjuvant chemotherapy does show a benefit in this patient population.
Read More
Use of Tumor-Infiltrating Lymphocytes Expanding in Breast Cancer
October 16th 2018The role of tumor-infiltrating lymphocytes (TILs) is expanding in cancer care, necessitating a more involved role for pathologists to quantify immune infiltrates, K.P. Siziopikou, MD, PhD, suggested during a presentation at the 2018 Lynn Sage Breast Cancer Symposium.
Read More
Analyzing the Role of Molecular Profiling in Patients With Metastatic Breast Cancer
October 15th 2018Patients with HER2-positive, microsatellite instability-high (MSI-H), and <em>NTRK</em> gene fusion-positive breast cancer likely benefit more than others from molecular profiling. In a presentation at the 2018 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Sledge discussed the growing use of molecular profiling, especially for metastatic cancers, as well said the decreasing cost of sequencing.
Read More
Scalp Cooling Closer to Widespread Use Following Expanded FDA Clearances
October 12th 2018Following recent FDA clearances, using scalp cooling to limit alopecia in patients receiving chemotherapy is closer to becoming a more common practice, according to a presentation at the 2018 Lynn Sage Breast Cancer Symposium.
Read More
Pontchartrain Cancer Center Pushes Limits of Community Care in Southeast Louisiana
September 27th 2018Pontchartrain Cancer Center was founded in 2005 to serve an area of Louisiana that lacked the necessary resources for cancer care. This community cancer center, with 2 locations in Southeast Louisiana, accommodates any patient to walk through its doors, filling a major unmet need for the community in this rural area.
Read More